Partial Agonist vs Full Agonist Opioids: What the Difference Means for Kratom, 7-OH, and Treatment

And Why It Matters More Than Anyone Told You

John Leonard | Founder, Pivot Protocols

Executive Summary

• Full agonists activate the mu-opioid receptor completely with no ceiling — producing the respiratory depression that makes overdose fatal. Partial agonists plateau below maximum activation, producing a real ceiling on respiratory depression. That ceiling does not extend to dependence. Every partial agonist in the clinical record produced physical dependence in regular users.

• 7-hydroxymitragynine is a high-potency partial agonist with short functional duration. That combination produces a distinct dependence pattern characterized by compressed reinforcement cycles, interval compression, sleep destruction, and progressive loss of cognitive and emotional regulation — not the full body burden of classical full agonist use, but opioid dependence in every clinically meaningful sense. This pattern has a clinical name: short cycle dependence. Those inside it have another name: short cycle hell.

• Standard buprenorphine induction protocols were built for full agonist opioids. The partial-to-partial displacement dynamic that defines 7-OH to buprenorphine transition may carry a fundamentally different precipitated withdrawal risk profile. The research to confirm or refute this does not yet exist. The Pharmacologic Cycle Overwrite recovers the original short-term detox clinical application of buprenorphine and applies it to a population it was always suited for. One novel hypothesis — the partial-to-partial precipitated withdrawal risk profile — is identified and offered as an invitation to formal research.

• MAT was developed for populations facing acute overdose mortality risk. That risk calculus does not transfer cleanly to 7-OH dependence. For this population, abstinence is often both the goal and the pharmacologically achievable outcome.

• The introduction of vaporized 7-OH delivery removes the last natural friction point from a product already producing serious dependence in oral format. It is entering a population kindled not only by prior opioid exposure but by the entire architecture of a consumer environment optimized for compressed reinforcement — including a generation that never had an unkindled baseline to begin with. The regulatory case for acting now is documented in Schedule 7-OH First.

Table of Contents

1. What a Full Agonist Does

2. The History of Partial Agonists — and Why the Safety Argument Keeps Failing

3. Where Kratom and 7-OH Sit on the Spectrum

4. Short Cycle Dependence — and What It Actually Feels Like

5. Why the Treatment Picture Changes — and What the PCO Proposes

6. What the Market Built — and What the Response Has to Be

There is a conversation happening in forums at 3am that the clinical literature has almost nothing useful to say about.

Someone is awake again. Heart racing. Sweating through the sheets. They took something a few hours ago — a shot, a tablet, something from the smoke shop or an online vendor — and now the effect is gone and the body is demanding it back. They are not a heroin addict. They have never touched a needle. They bought something that was supposed to help with pain, or energy, or anxiety. The label said botanical. The checkout process required no prescription.

But the body doesn’t read labels.

What that person is experiencing is opioid withdrawal. Not metaphorically. Not approximately. The same receptor system, the same neurochemical cascade, the same desperate biology — just triggered by a compound that most clinical frameworks haven’t caught up with yet.

Understanding why this happens requires understanding something that almost nobody explains clearly at the point of purchase, in the forums, or in the clinical literature on kratom and 7-OH.

It requires understanding the difference between a full agonist and a partial agonist. And more importantly, it requires understanding why that distinction — which has been used repeatedly as a safety argument — keeps turning out to be more complicated than it sounds.

This is that explanation. Written for the person waking up at 3am, the clinician seeing this population for the first time, and the policy maker trying to understand why a botanical supplement is producing an opioid dependence pattern in people who never saw it coming.

1. What a Full Agonist Does

The mu-opioid receptor modulates pain, stress response, emotional tone, reward signaling, and the body’s sense of baseline stability. Full agonists — morphine, heroin, oxycodone, fentanyl, methadone — activate that receptor completely. They drive the signal to its ceiling with no pharmacological brake. The higher the exposure, the stronger the activation, all the way up to the point where respiratory depression becomes fatal.

That ceiling-free activation is both what makes full agonists effective for severe pain and what makes them dangerous. The therapeutic window narrows as tolerance builds. And tolerance builds reliably because the nervous system does what it always does when a powerful signal arrives consistently: it adapts. Receptors downregulate. Stress systems upregulate. The body recalibrates around the new normal.

When that signal disappears, the stress systems that were being suppressed rebound. Hard.

That rebound is withdrawal.

The physical toll of full agonist use is system-wide. Respiratory suppression is the overdose mechanism — the brain stops sending the signal to breathe. Severe constipation reflects full activation of gut opioid receptors. Hormonal suppression affects testosterone, estrogen, and libido. Methadone carries a specific cardiac risk through QT interval prolongation. Cognitive function degrades with long-term use in ways that outlast acute intoxication.

That risk profile is what drove the search for alternatives. Partial agonists entered that conversation as a pharmacologically sophisticated answer to a real clinical problem.

Whether they delivered on that promise is a more complicated story.

2. The History of Partial Agonists — and Why the Safety Argument Keeps Failing

The theoretical promise of partial agonism was compelling: activate the mu-opioid receptor enough to produce analgesia and relieve withdrawal, but not enough to drive the full cascade of respiratory depression and euphoria.

The clinical history of that promise is a pattern of repetition.

Pentazocine arrived in 1967 as a marketed non-addictive alternative to morphine. Nalbuphine — Nubain — followed as an unscheduled partial agonist accessible enough that it became a drug of abuse before the safety narrative caught up with the pharmacology. Tramadol arrived in the US in 1995 with a dual mechanism — partial opioid agonism plus serotonin-norepinephrine reuptake inhibition — and was prescribed at extraordinary scale on the strength of its partial agonist positioning. It produced dependence. It produced a withdrawal syndrome with simultaneous opioid and antidepressant discontinuation components. Its serotonergic mechanism carried a seizure risk that point-of-prescribing rarely communicated. It was scheduled in 2014 — nearly two decades after introduction.

Each compound produced physical dependence in regular users. Each time, the partial agonist classification was used to support a safety narrative that the full pharmacological picture didn’t sustain.

That is the one consistent lesson across the entire partial agonist record: the ceiling on respiratory depression is real. The ceiling on dependence is not.

Buprenorphine is the most clinically successful chapter — its partial agonism paired with high receptor affinity and long half-life produced stable, predictable occupancy that aligned well with the clinical goal of long-duration maintenance. It is the partial agonist that most closely delivered on the original promise. But it too produces dependence, requires a taper for discontinuation, and carries a withdrawal profile that many patients describe as more difficult than what brought them to treatment.

7-hydroxymitragynine is the current chapter. It arrived without a prescription requirement, without a pharmacist, and without any of the clinical infrastructure that took decades to build around the compounds that came before.

3. Where Kratom and 7-OH Sit on the Spectrum

Kratom’s primary alkaloid, mitragynine, is a partial mu-opioid receptor agonist with lower intrinsic efficacy than morphine or buprenorphine. In traditional leaf form it produced a mild, relatively long-duration effect with moderate dependence potential. That reputation was not entirely wrong — for the leaf, in traditional preparation, at traditional exposure levels.

What it failed to anticipate was extraction and concentration. Concentration increases potency. Increased potency drives faster tolerance. Faster tolerance drives increased frequency. Increased frequency compresses the reinforcement cycle. A compound mild and long-duration in its natural form begins behaving like something else entirely.

7-hydroxymitragynine is a different story from the beginning. It occurs naturally in the kratom leaf in very small concentrations but is significantly more potent at the mu-opioid receptor than mitragynine — a gap that research on kratom alkaloid pharmacology documents clearly. When concentrated and isolated into retail extract products, that potency is amplified dramatically. (Hemby et al., 2019)

But potency alone doesn’t explain the short cycle pattern. The other half is duration.

7-OH has a short functional duration. Rapid onset. Steep activation curve. Rapid decline. Early withdrawal onset. The compound activates the receptor powerfully and then clears quickly — producing a sharp rise and a sharp fall, repeatedly, throughout the day and night.

That cycle is what the framework calls a reinforcement cycle. When those cycles compress — when the time between them shortens as tolerance builds — the nervous system enters a state of sustained instability that standard taper protocols were not designed to address.

4. Short Cycle Dependence — and What It Actually Feels Like

The person dependent on concentrated 7-OH products often has no clinical framework for what is happening to them. They don’t identify as an opioid addict. They bought something at a gas station or online. Nothing about the point of purchase announced what they were actually taking.

What they are experiencing has a clinical name: short cycle dependence.

Those inside it have another name for it.

Short cycle hell.

The clinical profile of short cycle dependence — its pattern characteristics, threshold indicators, mechanistic basis, and differentiation from other dependence frameworks — is documented here:

→ Short-Cycle Opioid Dependence (SCOD): Clinical Framework

7-OH dependence does not feel like heroin dependence. The full body burden of classical full agonist use — severe constipation, hormonal suppression, respiratory risk, heavy cognitive obliteration — is significantly attenuated. Because 7-OH is a partial agonist it engages pain modulation and reward pathways effectively without driving full systemic mu-opioid activation to the degree a full agonist does. The result is genuine opioid effect — real analgesia, real euphoria, pinpoint pupils, sedation at higher levels — with a side effect profile measurably lighter than full agonist alternatives.

That difference is clinically interesting. It is also commercially dangerous. A compound that produces strong opioid effect with fewer obvious physical consequences is easier to use at higher frequency without the warning signs that might otherwise prompt recognition of what is happening.

As tolerance builds the functional duration shortens. Interval compression sets in — the time between uses becomes progressively shorter not by choice but by pharmacological necessity.

Sleep becomes the first casualty. The short cycle doesn’t pause at night. The compound clears. Early withdrawal signals appear. The person wakes — heart racing, sweating, unable to settle — every two to three hours. The night becomes a series of mini withdrawal events. The nervous system never fully lands.

Emotional regulation follows. Waves of anxiety or dread arrive on a schedule tied to the use cycle. Cognitive bandwidth collapses. The future compresses to the length of a reinforcement cycle. Financially, short cycle dependence becomes extremely expensive — using multiple times a day simply to stay functional, not to get high, can cost hundreds of dollars a day.

The Vape Changes the Equation

Oral 7-OH products already produce short cycle dependence in a population that didn’t see it coming. Vaporized delivery removes the last natural friction point.

Oral formats have a delayed onset of ten to thirty minutes. That delay created spacing. Intervals gave the nervous system brief windows to exist without a signal. Vaporized delivery collapses that window entirely. When effects arrive in seconds, the gap between discomfort and response effectively disappears. The nervous system stops expecting stability between uses. It begins expecting only the next correction.

The loop has no gaps. And a nervous system that lives inside a loop with no gaps eventually stops expecting any.

The Kindled Population

Forty years of opioid market evolution has produced a large population whose nervous systems have been shaped by repeated opioid receptor exposure. A nervous system that has been through opioid dependence — once, or repeatedly — encounters 7-OH as a kindled system. The cycle establishes faster. The intervals compress sooner.

But the opioid-exposed population is only part of the picture.

There is a generation that walks into the smoke shop having never had a baseline to lose — already kindled by everything else.

They grew up inside compressed reinforcement across every domain simultaneously. TikTok before they could drive. Sports betting apps before they graduated. Ultra-processed food engineered for palatability peaks. An environment that recalibrated reinforcement thresholds during the developmental window when the nervous system was still establishing the baseline it carries forward for life.

Their thresholds were not recalibrated by exposure. They were set low from the beginning.

When a 7-OH vape with near-instant onset and no natural gaps enters that nervous system, it doesn’t encounter resistance. It encounters recognition. The kindled generation didn’t arrive at vulnerability through prior opioid exposure. They arrived at it through the entire architecture of the consumer environment they grew up in.

Why This Population Is Invisible to Treatment

The person in short cycle dependence often doesn’t present in treatment settings. They are high functioning by external measures. The absence of obvious full agonist impairment markers means the people around them don’t see it either.

They are in forums at 3am. They are attempting tapers that keep collapsing at the same point, over and over, without understanding why.

They are not failing because of weakness. Short cycle dependence destroys the neurological infrastructure that tapering requires. Asking someone in this state to taper is not a clinical strategy. It is a test of willpower administered to a nervous system that can no longer reliably produce it.

5. Why the Treatment Picture Changes — and What the PCO Proposes

Buprenorphine induction protocols were developed in the context of full agonist opioid dependence. The assumptions embedded in those protocols were built around heroin, oxycodone, and fentanyl. The partial-to-partial transition that defines 7-OH to buprenorphine induction was not part of that literature. It still largely isn’t.

This is the point at which the standard treatment model stops mapping cleanly onto the pattern being described.

The central clinical fear in buprenorphine induction is precipitated withdrawal — the abrupt destabilization that occurs when buprenorphine displaces a full agonist at peak receptor activation. That model is well established for heroin and fentanyl. But 7-OH is not a full agonist.

When buprenorphine displaces 7-OH during its descending phase — as early withdrawal signals are already appearing — the net receptor activation delta may differ fundamentally from classical full agonist displacement. The compound being displaced is already declining. Buprenorphine may stabilize a falling system rather than precipitate a crash.

The induction window for this population is therefore not primarily a question of hours since last use. It is a question of where on the descending activation curve the system currently sits. Early withdrawal signals — not full acute withdrawal, and not peak activation — may represent the optimal window. That distinction has significant clinical implications that existing protocols do not account for.

The Pharmacologic Cycle Overwrite

The PCO is a targeted, time-limited buprenorphine loading strategydesigned to accomplish one thing: the immediate and complete replacement of a compressed unstable partial agonist cycle with a single stable pharmacological platform.

Short cycle dependence has two defining features that make standard taper approaches fail. First, the nervous system has been stripped of the regulatory capacity tapering requires. Second, the compressed cycle prevents the intervals stabilization needs. There are no gaps to work with.

The PCO addresses both simultaneously. Strategic loading to receptor saturation eliminates the short cycle in a single decisive intervention. The overwrite announces its own completion — when additional buprenorphine produces no perceptible effect, the receptors are occupied and the cycle has no foothold left to reassert from.

What follows is not maintenance. It is exit.

Aggressive tapering begins immediately after saturation — days, not weeks. The buprenorphine half-life continues working passively after the final use. The acute withdrawal phase resolves as plasma concentrations decline. The nervous system begins recovery from stability rather than crisis.

A Word About MAT

The population described in this paper will look, to clinicians trained in medication-assisted treatment, like a natural candidate for buprenorphine maintenance. The induction may be smoother than classical full agonist induction. The population is often high-functioning and privately paying.

It is worth pausing on that assumption.

MAT was developed primarily for populations facing acute overdose mortality risk. The clinical justification for accepting one dependency to manage another is most defensible when the alternative is fentanyl and death is a realistic near-term outcome. In that context the risk-benefit calculation is well supported by the literature.

7-OH dependence presents a different risk profile. The partial agonist ceiling on respiratory depression meaningfully reduces — though does not eliminate — the overdose mortality risk that defines the fentanyl crisis. The mortality urgency that established MAT as the standard of care for opioid dependence is not present in the same way.

That distinction matters clinically. Transitioning a 7-OH dependent patient to indefinite buprenorphine maintenance trades one dependency for another with its own discontinuation profile — one that many patients describe as unexpectedly difficult. For a population whose primary goal is freedom from the cycle, and whose mortality risk does not require maintenance as a harm reduction imperative, that outcome warrants careful consideration before it becomes the default.

The PCO proposes a different clinical frame. Buprenorphine as a precision instrument with a defined lifespan — used to overwrite the compressed cycle and exit cleanly through pharmacokinetic self-tapering. For this population, abstinence is often both the goal and the pharmacologically achievable outcome. The treatment approach should reflect that.

6. What the Market Built — and What the Response Has to Be

The story told in this paper is not a new story. A partial agonist enters a market. The pharmacological classification supports a safety narrative. The safety narrative is incomplete. The dependence potential is real. The clinical infrastructure doesn’t exist yet. By the time the pattern becomes impossible to ignore, the market has moved on.

Pentazocine. Nalbuphine. Tramadol. 7-hydroxymitragynine.

The same chapter. A different compound.

7-OH arrives with two features that make it more urgent than its predecessors. The retail infrastructure distributes it without a prescriber, a pharmacist, or an accurate warning label. And the vape removes the last natural friction point from a product already producing serious dependence in oral format.

The full architecture of how that trajectory developed — from plant medicine to concentrated alkaloid products distributed through retail markets without prescription or clinical oversight — is documented in the Retail Pharmacologyseries.

That product is in retail markets now. It looks like a nicotine vape. It requires no prescription. It is entering a population whose thresholds were set low not by prior opioid exposure alone but by the entire architecture of a consumer environment optimized for compression — and a generation that never had a different baseline to return to.

The clinical frameworks designed to address opioid dependence were not built for this. What this population needs is a framework built for the pattern they are actually in — one that recognizes short cycle dependence as a distinct clinical entity, addresses the partial-to-partial induction dynamic honestly, and holds abstinence as the achievable goal for a population whose mortality risk does not require indefinite maintenance as the default outcome.

The Pharmacologic Cycle Overwrite is a proposal in that direction. The regulatory case is documented in Schedule 7-OH First. The clinical framework is documented in the Pharmacologic Cycle Overwrite.

The person waking up at 3am in short cycle hell is not a statistic in a policy paper. They are the endpoint of a forty-year market trajectory — a pharmacological story that kept repeating because the partial agonist safety narrative kept being accepted before the full clinical picture emerged.

They deserve a framework built for what they are actually experiencing.

The research needs to begin. The regulatory window is open. The clinical conversation has a starting point.

This is part of that starting point.

John Leonard
Founder, Pivot Protocols | Stability Architect
23 years in frontline recovery program leadership

For the pharmacological background, see the Retail Pharmacologyseries. For the regulatory argument, see Schedule 7-OH First. For the clinical framework, see the Pharmacologic Cycle Overwrite.

If you are a clinician, researcher, or policy advocate interested in the framework described here, contact information is available through Pivot Protocols.

If this pattern sounds familiar — this takes 30 seconds. No email required. Build Your Quit Plan

Selected References

Hemby SE, McIntosh S, Leon F, Cutler SJ, McCurdy CR. Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine. Addiction Biology. 2019;24(5):874-885. doi:10.1111/adb.12639. PMID: 29949228.

U.S. Department of Health and Human Services. Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder. Washington, DC: HHS; April 2021. Available at: https://www.federalregister.gov/documents/2021/04/28/2021-08961/practice-guidelines-for-the-administration-of-buprenorphine-for-treating-opioid-use-disorder